ARTES, instrAction and Q‑Biologicals Join Forces for Veterinary Vaccine Development

Under the title:” devel­op­ment of a virus-like-par­ti­cle (VLP) based vac­cine plat­form and sta­ble for­mu­la­tion espe­cial­ly suit­ed for the vet­eri­nary appli­ca­tions”, in short “Pluri­vax”, the EU coop­er­a­tion is part of the recent 8th Euro­Trans­Bio call and will be fund­ed for a three year peri­od sup­port­ed by the Ger­man Fed­er­al Min­istry of Edu­ca­tion and Research (BMBF) and the Flan­ders (Bel­gium) agency for Inno­va­tion by Sci­ence and Tech­nol­o­gy (IWT).

The intent of “Pluri­vax” is to devel­op a sta­ble pro­duc­tion plat­form and an adapt­ed high-qual­i­ty process to have an effec­tive and usable inte­grat­ed best prac­tice suit­able for sev­er­al vet­eri­nary vaccines.The plat­form result­ing from this project will be the first of its kind in vet­eri­nary appli­ca­tion and thus opens access to a huge mar­ket. A robust, inex­pen­sive vac­cine will reduce the need for antibi­ot­ic treat­ment of food ani­mals, there­by direct­ly reduc­ing pro­duc­tion costs and improv­ing qual­i­ty of life for the food ani­mal itself and for the consumer.

ARTES VLP plat­form METAVAX® has already been applied to the devel­op­ment of adju­vant-free vac­cines against dif­fer­ent dis­eases like avian and swine flu, malar­ia and HIV. Our yeast expres­sion host Hansenu­la is the pre­ferred tech­nol­o­gy for afford­able mass vac­ci­na­tion and is rec­om­mend­ed by the WHO for mass vac­ci­na­tions. Togeth­er, our plat­forms build an excel­lent approach to low-cost mass pro­duc­tion of safe and effec­tive vac­cines”, Michael Pio­ntek, Man­ag­ing Direc­tor of ARTES.

Annie Van Broekhoven, CEO Q‑Biologicals com­ments: “We will employ our know-how and exper­tise in the field of bio­process devel­op­ment, man­u­fac­tur­ing and for­mu­la­tion of recom­bi­nant anti­gens to devel­op a robust pro­duc­tion process for VLP based vac­cines. We are con­fi­dent that we will suc­ceed in short­en­ing the process devel­op­ment times con­sid­er­ably, and in doing so dri­ve down devel­op­ment costs and sup­port rapid mar­ket introduction.”

We will con­tribute our tai­lor made but com­pet­i­tive­ly priced plat­form purifi­ca­tion process to this cost sen­si­tive pro­duc­tion process­es. Our pro­pri­etary chro­matog­ra­phy phase tech­nol­o­gy, already being used for purifi­ca­tion of com­mer­cial bio­phar­ma­ceu­ti­cals and small mol­e­cule APIs, allows spe­cif­ic bind­ing of tar­get mol­e­cules and can be trans­ferred to almost every chro­mato­graph­ic car­ri­er sub­strate”, Peter Kallien, CFO of instrAction.